Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
Artesunate is an intravenous artemisinin derivative indicated for severe malaria. It is a fast-acting antimalarial agent that reduces parasite burden rapidly. The drug represents a critical treatment option for life-threatening malaria infections.
The product is at peak commercial stage with established market presence and limited competitive pressure, suggesting stable mid-sized brand team focused on optimization and market penetration.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study Evaluating the Efficacy and Safety of Artesunate
Evaluation of Artesunate in Infants Being Treated for Severe Malaria
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
Artesunate Pessaries (Vaginal Inserts) for Cervical Precancer in Kenya
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
Worked on ARTESUNATE at Amivas? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moArtesunate represents a peak-stage specialty IV product with significant unmet need positioning but currently shows zero linked job openings, suggesting stable established team. This is a solid portfolio product for career professionals seeking established brand management rather than rapid growth expansion.